Fig. 3From: Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinomaDistribution of histopathologic response (residual cancer cells) in the resected primary tumors across PODXL expression in the pre-neoadjuvant biopsiesBack to article page